PRUSOGLIPTIN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H25FN4O2
Molecular Weight	324.3937
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(CC(=O)N1CCCC1)NCC(=O)N2C[C@@H](F)C[C@H]2C#N

InChI

InChIKey=VQKSCYBKUIDZEI-STQMWFEESA-N

InChI=1S/C16H25FN4O2/c1-16(2,8-14(22)20-5-3-4-6-20)19-10-15(23)21-11-12(17)7-13(21)9-18/h12-13,19H,3-8,10-11H2,1-2H3/t12-,13-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20483603
Curator's Comment: description was created based on several sources, including http://www.clinicalleader.com/doc/scinopharm-and-national-health-research-0001

DBPR-108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9, which is in phase I clinical trial as a potential treatment of type 2 diabetes.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dipeptidyl peptidase IV 37 Target ID: CHEMBL4653 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20483603	Inhibitor 8504		15.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: http://www.clinicalleader.com/doc/scinopharm-and-national-health-research-0001	Palliative		Phase I 438	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32338063	unhealthy, 52.59 Health Status: unhealthy Age Group: 52.59 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/32338063	Sources: https://pubmed.ncbi.nlm.nih.gov/32338063

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P008U2D	https://www.1pchem.com/search?query=1P008U2D
AChemBlock	P50908	http://www.achemblock.com/catalogsearch/result/?q=P50908
BLD Pharm	BD629964	http://www.bldpharm.com/search/Search.html?keyword=BD629964
Chem Scene	CS-3825	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3825
ChemShuttle	157284	https://www.chemshuttle.com/catalogsearch/result/?q=157284
eMolecules	275136849	https://orderbb.emolecules.com/search/#?query=275136849
eMolecules	302053879	https://orderbb.emolecules.com/search/#?query=302053879
eMolecules	53744848	https://orderbb.emolecules.com/search/#?query=53744848
Lab Network	LN01342441	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01342441
mcule	MCULE-5047272043	https://mcule.com/MCULE-5047272043/
mcule	MCULE-9429260794	https://mcule.com/MCULE-9429260794/
MedChem Express	HY-12528	https://www.medchemexpress.com/search.html?q=HY-12528&ft=&fa=&fp=
Molnova	M10635	https://www.molnova.com/en/serch-list.html?keywords=M10635
MolPort	MolPort-046-416-909	https://www.molport.com/shop/molecule-link/MolPort-046-416-909

PubMed

Title	Date	PubMed
(2S,4S)-1-[2-(1,1-dimethyl-3-oxo-3-pyrrolidin-1-yl-propylamino)acetyl]-4-fluoro-pyrrolidine-2-carbonitrile: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.	2010-06-15	20483603

Patents

Sample Use Guides

In Vivo Use Guide

DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

DBPR-108

Preferred Name

English

PRUSOGLIPTIN

Official Name

English

prusogliptin [INN]

Common Name

English

(2S,4S)-4-FLUORO-1-(((2-METHYL-4-OXO-4-(PYRROLIDIN-1- YL)BUTAN-2-YL)AMINO)ACETYL)PYRROLIDINE-2-CARBONITRILE

Systematic Name

English

2-PYRROLIDINECARBONITRILE, 1-(2-((1,1-DIMETHYL-3-OXO-3-(1-PYRROLIDINYL)PROPYL)AMINO)ACETYL)-4-FLUORO-, (2S,4S)-

Systematic Name

English

Prusogliptin [WHO-DD]

Common Name

English

(2S,4S)-1-(2-((1,1-DIMETHYL-3-OXO-3-(1-PYRROLIDINYL)PROPYL)AMINO)ACETYL)-4-FLUORO-2-PYRROLIDINECARBONITRILE

Systematic Name

English

Code System Code Type Description

INN

11627